Biomarkers for cancer‑related fatigue and adverse reactions to chemotherapy in lung cancer patients
- Authors:
- Published online on: October 8, 2014 https://doi.org/10.3892/mco.2014.439
- Pages: 163-166
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
This study was conducted to investigate the biomarkers that appear to be correlated with cancer‑related fatigue (CRF) and the adverse reactions (ADRs) to chemotherapy. A total of 100 lung cancer patients were selected and CRF prior to and following chemotherapy was evaluated. The plasma levels of tumor necrosis factor (TNF)‑α and interleukin (IL)‑1 and the level of 17‑hydroxycorticosteroid (17‑OHCS) in the urine were analyzed and correlated with CRF and the ADRs associated with chemotherapy. The incidence of CRF was found to be 88.0% and ADRs following chemotherapy occurred in 15.0% of the patients. An increase in the TNF‑α and IL‑1 levels was detected in patients with CRF. The level of 17‑OHCS in the urine was found to be elevated in cases that experienced ADRs following chemotherapy. In conclusion, CRF is closely correlated with increased plasma levels of TNF‑α and IL‑1. Furthermore, an abnormally elevated 17‑OHCS level in the urine may be an important indicator predicting ADR development following chemotherapy.
